Major announcements in focus:

BIDU-SW (09888) has voluntarily converted to dual-primary listing on the Hong Kong Stock Exchange. CHINA BAOLI TEC (00164) has made significant progress deploying its dry grinding and dry separation operations in Mongolia. CONSUN PHARMA (06955) has received CDE acceptance for its BA2201 (TL1A/IL-23) clinical trial application. CanSino Biologics (06185)'s subsidiary has entered into a strategic cooperation framework agreement with Depushi Biologics for the co-development of mRNA personalized therapeutic tumor vaccines. BUTONG GROUP (06090) reported a 98.28% year-on-year increase in profit, nearly doubling, and plans to intensify AI upgrades for its core products.

Financial results summary:

CHINA RES POWER (00836) posted interim results with shareholders' attributable profit of HK$6.649 billion, down 15.53% year-on-year. CONSUN PHARMA (01681) reported interim profit attributable to shareholders of RMB 595 million, up 19.5% year-on-year, with nephrology product sales rising approximately 18.1%. Shijiazhuang No.4 Pharmaceutical (02005) announced interim results with shareholders' profit of HK$320 million, up 12.99%. COFCO Joycome (01610) posted interim results showing a loss of RMB 1.553 billion attributable to owners after fair value adjustments on biological assets, turning from profit to loss year-on-year.

Four Rings Pharma (00460) released interim results with shareholders' profit of RMB 225 million, up 119%, continuing its dual-driven strategy of "medical aesthetics plus innovative drugs". CHINA OVERSEAS (00688) reported interim profit attributable to shareholders of approximately RMB 7.03 billion, down 18.24%, with an interim dividend of HK$0.23 per share. ANTA Sports (02020) announced interim results with shareholders' profit of RMB 9.487 billion, up 34.9% year-on-year. China Communications Services (00552) posted interim results with net profit of RMB 1.97 billion, down 7.5%. Li Auto-W (02015) recorded a net loss of RMB 1.705 billion in the second quarter, swinging to a loss year-on-year.

Meitu (01357) released interim results with shareholders' profit of RMB 619 million, up 40%, while monthly active users (MAU) hit a record high. CNOOC (00883) reported interim results with net profit attributable to shareholders of RMB 85.818 billion, up 23.42% year-on-year, achieving its best-ever first-half performance. BOCOM International (03329) saw significant improvements, with investment banking revenue growing more than threefold. New China Life (01336) announced interim results with net profit attributable to shareholders up 54% to RMB 22.793 billion, with a dividend of RMB 0.73 per share.

Hansoh Pharma (03692) posted interim results with shareholders' profit of RMB 4.258 billion, up 35.82%. Haitian Flavoring (03288) reported interim results with net profit of RMB 4.19 billion, up 7.13%. Huishang Bank (03698) announced interim results with net profit attributable to shareholders of RMB 9.203 billion, up 1.03%. Sunny Optical Technology (02382) released interim results with shareholders' profit of RMB 1.808 billion, up 9.86%. CITIC Bank (00998) posted interim results with net profit attributable to shareholders of RMB 37.602 billion, up 3.08%. Sinotruk Hong Kong (03808) announced interim results with shareholders' profit of RMB 4.325 billion, up 26.22%.

Yikong Zhijia (07687) achieved a 844.3% increase in first-half gross profit, maintaining the top market position with over 53% share. Naixue Tea (02150) generated revenue of RMB 1.8925 billion in the first half, continuously enriching its product portfolio. China Resources Beverage (02460) released interim results with shareholders' profit of RMB 592 million, firmly pursuing its brand-driven development strategy. Zheshang Bank (02016) announced interim results with net profit attributable to shareholders of RMB 7.824 billion, up 2.05%.

Tsingtao Brewery (00168) reported interim results with net profit attributable to shareholders of approximately RMB 3.92 billion, up 0.4%. Anhui Conch Cement (00914) posted interim results with shareholders' profit of RMB 2.72 billion, down 41.85%. Grand Pharma (00512) saw a 55.4% surge in revenue from its nuclear medicine anti-tumor segment, with a robust pipeline awaiting key R&D milestones from 2027 to 2028. China Mengniu Dairy (02319) announced interim results with shareholders' profit of RMB 2.371 billion, up 15.94% year-on-year.